Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:phosphodiesterase_inhibitor
gptkb:chemical_compound |
| gptkbp:ATCCode |
N06AX10
|
| gptkbp:CASNumber |
61413-54-5
|
| gptkbp:category |
gptkb:antidepressant
gptkb:phosphodiesterase_inhibitor |
| gptkbp:chemicalFormula |
C16H21NO3
|
| gptkbp:developedBy |
gptkb:Schering_AG
|
| gptkbp:discoveredBy |
1970s
|
| gptkbp:IUPACName |
4-(3-cyclopentyloxy-4-methoxyphenyl)pyridin-2-ylamine
|
| gptkbp:mechanismOfAction |
selective inhibitor of phosphodiesterase-4 (PDE4)
|
| gptkbp:molecularWeight |
275.34 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1427
5096 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting gastrointestinal disturbances |
| gptkbp:synonym |
ZK 62.711
4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidinone |
| gptkbp:UNII |
QZJ8XJ0FLY
|
| gptkbp:used_in_research_for |
neurodegenerative diseases
anti-inflammatory effects antidepressant effects |
| gptkbp:bfsParent |
gptkb:Cyclic_Phosphodiesterase
gptkb:Phosphodiesterase |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
rolipram
|